Strides Pharma
Stock Snapshot
Price Performance
Vista Outlook
View Technicals Analysis →Basis of our Recommendation
Strides Pharma's recent management commentary highlights a focus on new product launches and a stable revenue trajectory, which are critical for maintaining its competitive position in the fragmented pharmaceutical market. Despite the anticipated margin pressures due to rising input costs, the company's strategic emphasis on higher-margin products and biosimilars aligns with Vista's forecast of stable revenue growth. The improving pricing power within the Indian pharmaceutical sector, coupled with favorable currency dynamics, supports Strides' long-term growth outlook. However, the company faces headwinds from potential pricing challenges in key markets and ongoing cost pressures. Over the next 12-24 months, Strides is positioned to leverage its strong pipeline, but investors should remain vigilant regarding margin sustainability and competitive dynamics. Vista's financial outlook reflects a cautious stance, with revenue growth expected to remain consistent with historical performance, while margins may experience continued pressure. The current valuation appears fair, with a modest expected upside, reinforcing the recommendation to hold. Key opportunities include the expansion of biosimilars, new product introductions, and favorable currency movements, while watchpoints include input cost inflation, pricing pressures, and competitive landscape shifts
Why We Like This Stock
- Focus on new product launches supports revenue stability and competitive positioning
- Improving pricing power in the Indian pharmaceutical sector enhances long-term growth prospects
- Strong pipeline of biosimilars aligns with market demand for innovative therapies
Things To Watch Out For
- Ongoing margin pressures due to rising input costs may impact profitability
- Potential pricing challenges in key markets could hinder revenue growth
- Fragmented competitive landscape may pose risks to market share stability
Key Parameters
Financial Snapshot
| Actuals | Forecast | ||||
|---|---|---|---|---|---|
| FY24 | FY25 | FY26 | FY27 | FY28 | |
| Revenue (Cr.) | 3,890 | 4,565 | 4,859 | 5,052 | 5,389 |
| Profit Before Tax (Cr.) | 72 | 416 | 696 | 726 | 774 |
| PBT Margin | 1.9% | 9.1% | 1432.4% | 14.4% | 14.4% |
| Net Profit (Cr.) | 119 | 3,559 | 614 | 642 | 665 |
| Earnings Per Share | 15.5 | 385.5 | 64.7 | 67.6 | 72.1 |
Analyst Recommendations
No analyst recommendations available.
Company Overview
Show Company Profile
Strides Pharma Science Limited develops, manufactures, and sells pharmaceutical products in Africa, Australia, North America, Europe, Asia, and internationally. The company offers pharma generics in various forms, such as tablets, hard and soft gelatin capsules, sachets, and liquids, as well as nasal spray, gels, powders, solids, ointments, and creams. It also develops branded generics products for the treatment of chronic therapies, including women's health, central nervous system, cardiovascular, diabetes, dermatology, and probiotics under the Renerve, Unibrol, Combiart, Duotab, and Vitafer brands; and anti-retroviral, anti-malarial, anti-tuberculosis, Hepatitis, and other infectious disease drug segments for institutional business. The company was formerly known as Strides Shasun Limited and changed its name to Strides Pharma Science Limited in July 2018. The company was incorporated in 1990 and is based in Bengaluru, India.